WikiGenes > Chemical > S1267_Selleckhttp://www.wikigenes.org/e/chem/e/42611257.html?wpc=6WikiGenes - Collaborative Publishingen-usCopyright 2026 - WikiGenesMon, 25 Jul 2016 06:50:45 GMTMon, 25 Jul 2016 06:50:45 GMT30Related informationhttp://www.wikigenes.org/e/ref/e/22028422.html#Tue, 8 Nov 2011 14:15:32 GMTHeakal, Y. et al.
Lineberger Comprehensive Cancer Center and North Carolina Cancer Hospital, College of Medicine, University of North Carolina, Chapel Hill, NC

Vemurafenib (PLX4032): An Orally Available Inhibitor of Mutated BRAF for the Treatment of Metastatic Melanoma.
Ann. Pharmacother. 2011; 11:1399-405

[See paper]]]>Tue, 8 Nov 2011 14:15:32 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/22431777.html#Wed, 18 Apr 2012 15:06:24 GMTAlloo, A. et al.
Department of Dermatology, Brigham and Women's Hospital, Emmanuel College, Alumnae Hall

Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.
Arch. Dermatol. 2012; 3:363-6

[See paper]]]>Wed, 18 Apr 2012 15:06:24 GMTBiology and medicine28 words added, 5 annot. addedhttp://www.wikigenes.org/e/chem/e/42611257.html?aid=pm22083257http://www.wikigenes.org/e/chem/e/42611257.html?vs1=0&vs2=1&wpc=6#Wed, 18 Apr 2012 17:54:50 GMTLuke, J.J. et al.
  1. Text changed:
    [Stub message]

    *** Disease relevance of Vemurafenib ***

    The development of vemurafenib, the role of BRAF targeting, and the changing landscape of treatment for melanoma provide a new foundation for clinical investigation [Ref].
     
[See latest version]    [See changes]    [See complete history]]]>Wed, 18 Apr 2012 17:54:50 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/22356324.html#Wed, 18 Apr 2012 19:42:02 GMTSosman, J.A. et al.
Vanderbilt-Ingram Cancer Center, Nashville, TN 37232-6307, USA

Vemurafenib induces clinical responses in more than half of patients with previously treated BRAF V600-mutant metastatic melanoma.
N. Engl. J. Med. 2012; 8:707-14

[See paper]]]>Wed, 18 Apr 2012 19:42:02 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/22180495.html#Fri, 20 Apr 2012 23:26:29 GMTYang, H. et al.
Authors' Affiliations: Discovery Oncology, Pharma Development, Roche Pharmaceuticals, Nutley, California

The addition of vemurafenib to capecitabine and/or bevacizumab, cetuximab and/or irinotecan, or erlotinib resulted in increased antitumor activity and improved survival in xenograft models.
Cancer Res. 2012; 3:779-89

[See paper]]]>Fri, 20 Apr 2012 23:26:29 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/22454415.html#Sat, 26 May 2012 15:08:13 GMTMcArthur, G.A. et al.
MB, BS, Division of Cancer Medicine and Research, Peter MacCallum Cancer Centre, Australia;

Marked, Homogeneous, and Early [18F]Fluorodeoxyglucose-Positron Emission Tomography Responses to Vemurafenib in BRAF-Mutant Advanced Melanoma.
J. Clin. Oncol. 2012; 14:1628-34

[See paper]]]>Sat, 26 May 2012 15:08:13 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/22559022.html#Sat, 26 May 2012 15:21:23 GMTWang, C.M. et al.
Department of Dermatology, Baylor College of Medicine, Houston, Texas

Successful treatment of metastatic melanoma with vemurafenib is not without significant adverse effects.
Dermatol. Online J. 2012; 4:7

[See paper]]]>Sat, 26 May 2012 15:21:23 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/21996740.html#Sat, 26 May 2012 16:36:20 GMTBasile, K.J. et al.
Department of Cancer Biology and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, USA

Small interfering RNA-mediated knockdown of FOXD3 significantly enhanced the cell death response after PLX4032/4720 treatment in mutant B-RAF melanoma cell lines.
Oncogene. 2012; 19:2471-9

[See paper]]]>Sat, 26 May 2012 16:36:20 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/22646765.html#Sun, 3 Jun 2012 09:12:27 GMTYoung, K. et al.
The Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK

The interim analysis results from this trial, BRIM-3, were sufficient for an independent data and safety monitoring board to recommend crossover from dacarbazine to vemurafenib, vemurafenib being associated with a relative risk reduction of 63% in the risk of death and 74% in the risk of death or disease progression compared with dacarbazine (p < 0.001 for both comparisons) with an acceptable toxicity profile.
Future. Oncol. 2012; 5:499-507

[See paper]]]>Sun, 3 Jun 2012 09:12:27 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/22646766.html#Sun, 3 Jun 2012 09:12:27 GMTPatrawala, S. et al.
Phase I Drug Development, Melanoma/Renal Cancer Program, Vanderbilt-Ingram Cancer Center, Division of Hematology-Oncology, USA

After review of the interim analysis by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.
Future. Oncol. 2012; 5:509-23

[See paper]]]>Sun, 3 Jun 2012 09:12:27 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/22454535.html#Tue, 26 Jun 2012 09:52:16 GMTMittapalli, R.K. et al.
Department of Pharmaceutics, University of Minnesota, 9-177 Weaver Densford Hall, 308 Harvard Street SE

These data indicate that the brain distribution of vemurafenib is severely restricted at the blood-brain barrier because of active efflux by both P-gp and BCRP.
J. Pharmacol. Exp. Ther. 2012; 1:33-40

[See paper]]]>Tue, 26 Jun 2012 09:52:16 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/22448344.html#Thu, 28 Jun 2012 10:03:08 GMTCorcoran, R.B. et al.
Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
Cancer. Discov. 2012; 3:227-35

[See paper]]]>Thu, 28 Jun 2012 10:03:08 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/22742884.html#Sat, 21 Jul 2012 10:20:00 GMTRavnan, M.C. et al.
Department of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, California

Vemurafenib is effective for advanced melanomas expressing the BRAF V600E mutations.
Clin. Ther. 2012; 7:1474-86

[See paper]]]>Sat, 21 Jul 2012 10:20:00 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/22913467.html#Mo, 7 Jän 2013 13:33:34 GMTSinha, R. et al.
Department of Dermatology, Chelsea and Westminster Hospital, London SW10 9NH, U.K.Departments of Medicine Dermatology, U.K

We provide a treatment algorithm offering guidance on the most appropriate approach to managing the main skin toxicities to help clinicians unfamiliar with this novel agent to become confident in using vemurafenib effectively in the management of patients with metastatic melanoma.
Br. J. Dermatol. 2012; 5:987-94

[See paper]]]>Mo, 7 Jän 2013 13:33:34 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/23060265.html#Mo, 7 Jän 2013 13:49:06 GMTBollag, G. et al.
Plexxikon, 91 Bolivar Drive, Berkeley, California 94710, USA

Following a rapid clinical development path, vemurafenib (Zelboraf; Plexxikon/Roche) was approved for the treatment of BRAF-mutated metastatic melanoma in the United States in August 2011 and the European Union in February 2012.
Nat. Rev. Drug. Discov. 2012; 11:873-86

[See paper]]]>Mo, 7 Jän 2013 13:49:06 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/22828249.html#Mo, 7 Jän 2013 15:39:49 GMTMinor, D.R. et al.
Center for Melanoma Research and Treatment, California Pacific Medical Center, San Francisco, California, USA

Desensitization may be possible in patients who develop Stevens-Johnson syndrome after vemurafenib treatment.
Melanoma Res. 2012; 5:410-1

[See paper]]]>Mo, 7 Jän 2013 15:39:49 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/22946753.html#Mo, 7 Jän 2013 17:34:41 GMTKeating, G.M.
Adis, Auckland, New Zealand

Oral vemurafenib was generally well tolerated in patients with metastatic melanoma, with cutaneous adverse events among the most commonly occurring adverse events.
BioDrugs. 2012; 5:325-34

[See paper]]]>Mo, 7 Jän 2013 17:34:41 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/22730329.html#Mo, 7 Jän 2013 18:47:22 GMTYadav, V. et al.
Oncology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, USA

Mechanistically, we found that the enhanced activation of fibroblast growth factor receptor 3 (FGFR3) is linked to Ras and MAPK activation, therefore conferring vemurafenib resistance.
J. Biol. Chem. 2012; 33:28087-98

[See paper]]]>Mo, 7 Jän 2013 18:47:22 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/23094782.html#Mo, 7 Jän 2013 18:59:20 GMTJordan, E.J. et al.
Waterford Regional Hospital, Department of Medical Oncology, Dunmore Road, Waterford, Ireland

Vemurafenib for the treatment of melanoma.
Expert. Opin. Pharmacother. 2012; 17:2533-43

[See paper]]]>Mo, 7 Jän 2013 18:59:20 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/22693252.html#Mo, 7 Jän 2013 22:23:51 GMTKoya, R.C. et al.
Department of Surgery, Division of Surgical Oncology, Crump Institute for Molecular Imaging, UCLA Biomedical Physics Interdepartmental Graduate Program, USA

BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.
Cancer Res. 2012; 16:3928-37

[See paper]]]>Mo, 7 Jän 2013 22:23:51 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/23093505.html#Mo, 7 Jän 2013 22:59:23 GMTFadaki, N. et al.
Department of Surgery, The Center for Melanoma Research and Treatment in California Pacific Medical Center, San Francisco, California, USA

Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib.
BMJ. Case. Rep. 2012;

[See paper]]]>Mo, 7 Jän 2013 22:59:23 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/22904646.html#Di, 8 Jän 2013 00:47:25 GMTFisher, R. et al.
Department of Medical Oncology, Royal Marsden Hospital, London, United Kingdom

This review summarizes the development of vemurafenib for the treatment of BRAF-V600 mutant melanoma and discusses how knowledge of critical signaling pathways will be applied for its optimal clinical use in future.
Cancer. Manag. Res. 2012; 243-52

[See paper]]]>Di, 8 Jän 2013 00:47:25 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/22431713.html#Di, 8 Jän 2013 01:16:14 GMTHuang, V. et al.
Division of Dermatology, Washington University in St Louis, St Louis, USA

The development of sorafenib-like cutaneous sequelae (squamous cell carcinomas, keratosis pilaris-like eruptions, seborrheic dermatitis-like rashes, and hand-foot skin reaction) associated with vemurafenib administration suggests that BRAF inhibition alone may be sufficient to induce these changes.
Arch. Dermatol. 2012; 5:628-33

[See paper]]]>Di, 8 Jän 2013 01:16:14 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/22651703.html#Do, 17 Jän 2013 11:27:13 GMTBaudy, A.R. et al.
Department of Biomedical Imaging, Genentech Inc, 1 DNA Way, South San Francisco, USA

We have demonstrated that 18 F-FDG-PET imaging reflects vemurafenib and GDC-0973 action across a wide range of metastatic melanomas.
EJNMMI. Res. 2012; 1:22

[See paper]]]>Do, 17 Jän 2013 11:27:13 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/23153455.html#Do, 2 Mai 2013 09:50:45 GMTWu, C.P. et al.
Department of Physiology and Pharmacology, Chang Gung University, Tao-Yuan 333, Taiwan

Taken together, our findings indicate that ABCG2 confers resistance to vemurafenib in A375 cells, suggesting involvement of this transporter in acquired resistance to vemurafenib.
Biochem. Pharmacol. 2013; 3:325-34

[See paper]]]>Do, 2 Mai 2013 09:50:45 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/22911096.html#Fr, 31 Mai 2013 09:35:13 GMTHaenssle, H.A. et al.

Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy.
Arch. Dermatol. 2012; 10:1183-5

[See paper]]]>Fr, 31 Mai 2013 09:35:13 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/23710269.html#Sa, 1 Jun 2013 09:37:54 GMTCohen, P.R. et al.
Department of Dermatology, University of California San Diego, San Diego, California

Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib.
J. Clin. Aesthet. Dermatol. 2013; 5:27-37

[See paper]]]>Sa, 1 Jun 2013 09:37:54 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/23699661.html#Do, 19 Dez 2013 12:00:46 GMTBoussemart, L. et al.

Vemurafenib should be considered a potential cutaneous radiosensitizer and an inducer of radiation recall dermatitis.
JAMA. Dermatol. 2013; 7:855-7

[See paper]]]>Do, 19 Dez 2013 12:00:46 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/24455362.html#Do, 30 Jän 2014 10:58:31 GMTMelnik, I. et al.

We present the first documented case in which vemurafenib induced complete tumor necrosis of both lymph node and brain metastases within one month or less, an outcome that indicated that the patient was a good candidate for excisional surgery.
Case. Rep. Oncol. Med. 2013; 794239

[See paper]]]>Do, 30 Jän 2014 10:58:31 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/23362240.html#Sa, 1 Feb 2014 10:05:22 GMTBeck, D. et al.

Moreover, the ER stress inducer thapsigargin prevented invasive growth of tumors formed from vemurafenib-sensitive melanoma cells in vivo.
Sci. Signal. 2013; 260:ra7

[See paper]]]>Sa, 1 Feb 2014 10:05:22 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/23457002.html#Wed, 16 Apr 2014 09:46:26 GMTLacouture, M.E. et al.

Dermatologic AEs associated with vemurafenib treatment in patients with melanoma were generally manageable with supportive care measures.
Oncologist. 2013; 3:314-22

[See paper]]]>Wed, 16 Apr 2014 09:46:26 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/23358426.html#Wed, 16 Apr 2014 11:33:38 GMTLee, J.M. et al.

Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report.
Melanoma Res. 2013; 2:175-8

[See paper]]]>Wed, 16 Apr 2014 11:33:38 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/24314265.html#Sun, 25 May 2014 09:36:59 GMTIddawela, M. et al.

This is the first reported case of end stage renal failure in a patient who is taking vemurafenib.
BMC. Cancer. 2013; 581

[See paper]]]>Sun, 25 May 2014 09:36:59 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/23489023.html#Sat, 21 Jun 2014 09:56:36 GMTKim, K.B. et al.

Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.
Thyroid. 2013; 10:1277-83

[See paper]]]>Sat, 21 Jun 2014 09:56:36 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/23436544.html#Fri, 4 Jul 2014 09:05:54 GMTMuluneh, B. et al.

To our knowledge, this is the first report of vemurafenib-induced pancreatitis.
Pharmacotherapy. 2013; 4:e43-4

[See paper]]]>Fri, 4 Jul 2014 09:05:54 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/23490205.html#Fri, 4 Jul 2014 09:18:30 GMTLe, K. et al.

Importantly, PB04 inhibited ERK1/2 phosphorylation in mutant BRAF melanoma cells with acquired resistance to vemurafenib/PLX4720 that is mediated by a secondary mutation in NRAS.
Pigment. Cell. Melanoma. Res. 2013; 4:509-17

[See paper]]]>Fri, 4 Jul 2014 09:18:30 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/24987354.html#Thu, 10 Jul 2014 09:45:57 GMTAli, S.M. et al.

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib.
Case. Rep. Oncol. 2014; 2:343-8

[See paper]]]>Thu, 10 Jul 2014 09:45:57 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/24508103.html#Wed, 20 Aug 2014 09:42:04 GMTMcArthur, G.A. et al.

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
Lancet Oncol. 2014; 3:323-32

[See paper]]]>Wed, 20 Aug 2014 09:42:04 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/24582505.html#Wed, 20 Aug 2014 09:42:17 GMTLarkin, J. et al.

Vemurafenib safety in this diverse population of patients with BRAF(V600) mutated metastatic melanoma, who are more representative of routine clinical practice, was consistent with the safety profile shown in the pivotal trials of this drug.
Lancet Oncol. 2014; 4:436-44

[See paper]]]>Wed, 20 Aug 2014 09:42:17 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/24289205.html#Sat, 8 Nov 2014 10:29:10 GMTWolf, S.E. et al.

Treatment with vemurafenib has become an important component of standard clinical care for patients with metastatic melanoma.
BMC. Cancer. 2013; 561

[See paper]]]>Sat, 8 Nov 2014 10:29:10 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/25364391.html#Sun, 9 Nov 2014 10:31:53 GMTDooley, A.J. et al.

Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series.
Ther. Adv. Med. Oncol. 2014; 6:262-6

[See paper]]]>Sun, 9 Nov 2014 10:31:53 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/24112705.html#Wed, 17 Dec 2014 10:38:32 GMTWagenaar, T.R. et al.

Our results identify a novel vemurafenib-resistant mutant and provide insights into the treatment for melanomas bearing this mutation.
Pigment. Cell. Melanoma. Res. 2014; 1:124-33

[See paper]]]>Wed, 17 Dec 2014 10:38:32 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/25037139.html#Wed, 17 Dec 2014 11:03:39 GMTRibas, A. et al.

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
Lancet Oncol. 2014; 9:954-65

[See paper]]]>Wed, 17 Dec 2014 11:03:39 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/24249714.html#Wed, 15 Apr 2015 10:10:36 GMTWang, J. et al.

Overall, these results offer a rational combination strategy to significantly enhance the therapeutic benefit in patients with melanoma who inevitably become resistant to current vemurafenib therapy.
Mol. Cancer Ther. 2014; 1:16-26

[See paper]]]>Wed, 15 Apr 2015 10:10:36 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/25265494.html#Wed, 15 Apr 2015 11:22:41 GMTLarkin, J. et al.

The addition of cobimetinib to vemurafenib was associated with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, at the cost of some increase in toxicity.
N. Engl. J. Med. 2014; 20:1867-76

[See paper]]]>Wed, 15 Apr 2015 11:22:41 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/24504444.html#Wed, 15 Apr 2015 12:58:49 GMTSchilling, B. et al.

During therapy, peripheral lymphocytes decreased by 24.3% (median, P < 0.0001) in vemurafenib-treated patients but remained unchanged in dabrafenib-treated patients (+1.2%, P = 0.717).
Ann. Oncol. 2014; 3:747-53

[See paper]]]>Wed, 15 Apr 2015 12:58:49 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/25745636.html#Wed, 15 Apr 2015 13:16:23 GMTEuskirchen, P. et al.

In this patient, vemurafenib was well-tolerated and highly efficacious for severe brainstem involvement in Erdheim-Chester disease with overlapping Langerhans cell histiocytosis.
Neurol. Neuroimmunol. Neuroinflamm. 2015; 2:e78

[See paper]]]>Wed, 15 Apr 2015 13:16:23 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/25729580.html#Wed, 15 Apr 2015 16:04:00 GMTGoldinger, S.M. et al.

A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma.
Pharmacol. Res. Perspect. 2015; 2:e00113

[See paper]]]>Wed, 15 Apr 2015 16:04:00 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/24755613.html#Mon, 24 Aug 2015 10:21:10 GMTCapalbo, C. et al.

Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: a case report.
Cancer Biol. Ther. 2014; 7:826-31

[See paper]]]>Mon, 24 Aug 2015 10:21:10 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/25063807.html#Mon, 24 Aug 2015 10:32:59 GMTLidsky, M. et al.

Together, the results indicate a mechanism of acquired vemurafenib resistance in V600E BRAF+ve melanoma cells that involves increased activation of all three human MAPKs and the PI3K pathway, as well as increased NRAS expression, which, contrary to previous reports, was not associated with mutations in the NRAS gene.
J. Biol. Chem. 2014; 40:27714-26

[See paper]]]>Mon, 24 Aug 2015 10:32:59 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/24445759.html#Mon, 24 Aug 2015 13:20:43 GMTFlaherty, L. et al.

This study confirmed the established rapid and high tumor response rate achievable with vemurafenib in BRAF mutation-positive metastatic melanoma.
Cancer. J. 2014; 1:18-24

[See paper]]]>Mon, 24 Aug 2015 13:20:43 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/25414333.html#Mon, 24 Aug 2015 17:13:00 GMTPeacock, M. et al.

DNA repair inhibition by UVA photoactivated fluoroquinolones and vemurafenib.
Nucleic Acids Res. 2014; 22:13714-22

[See paper]]]>Mon, 24 Aug 2015 17:13:00 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/25515496.html#Mon, 24 Aug 2015 17:44:58 GMTBoudewijns, S. et al.

Case series: indoor-photosensitivity caused by fluorescent lamps in patients treated with vemurafenib for metastatic melanoma.
BMC. Cancer. 2014; 967

[See paper]]]>Mon, 24 Aug 2015 17:44:58 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/24756795.html#Sun, 30 Aug 2015 09:25:03 GMTGarbe, C. et al.

The clinical trials with vemurafenib in unresectable metastatic melanoma in phase I, II, and III for patients harbouring BRAF V600E mutations demonstrated all unexpected high objective response rates ranging between 50 and 80%.
Recent Results Cancer Res. 2014; 215-25

[See paper]]]>Sun, 30 Aug 2015 09:25:03 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/25557167.html#Tue, 17 Nov 2015 13:08:48 GMTRoos, W.P. et al.

This leads to the question whether vemurafenib and alkylating agents act synergistically and whether chronic vemurafenib treatment alters the melanoma cell response to alkylating agents.
Oncotarget. 2014; 24:12607-20

[See paper]]]>Tue, 17 Nov 2015 13:08:48 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/26328215.html#Tue, 17 Nov 2015 13:11:42 GMTHagen, B. et al.

Vemurafenib has been approved for the treatment of patients with BRAF (V600E)-positive unresectable or metastatic melanoma based on survival benefit demonstrated in a randomized phase III study.
J. Adv. Pract. Oncol. 2014; 6:400-10

[See paper]]]>Tue, 17 Nov 2015 13:11:42 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/26557775.html#Tue, 17 Nov 2015 13:13:01 GMTRutkowski, P. et al.

At data cut-off, 28 patients died (37%), mainly (26) due to disease progression; 33 (44%) patients continued vemurafenib after disease progression.
Contemp. Oncol. (Pozn). 2015; 4:280-3

[See paper]]]>Tue, 17 Nov 2015 13:13:01 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/25706985.html#Wed, 18 Nov 2015 08:13:31 GMTJoshi, M. et al.

Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
PLoS. ONE. 2015; 2:e0118210

[See paper]]]>Wed, 18 Nov 2015 08:13:31 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/26579371.html#Thu, 17 Dec 2015 11:23:58 GMTWu, C.P. et al.

In this review, we highlight some of the recent findings related to the effect of ABC drug transporters such as ABCB1 and ABCG2 on the oral bioavailability of vemurafenib, problems associated with treating melanoma brain metastases and the development of acquired resistance to vemurafenib in cancers harboring the BRAF (V600E) mutation.
Acta. Pharm. Sin. B. 2014; 2:105-11

[See paper]]]>Thu, 17 Dec 2015 11:23:58 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/24823520.html#Wed, 23 Dec 2015 08:30:51 GMTShailesh, F.N. et al.

We hereby present a case of bilateral facial palsy as an adverse effect of vemurafenib therapy, seen after six weeks of commencement of the drug.
J. Postgrad. Med. 2014; 2:187-8

[See paper]]]>Wed, 23 Dec 2015 08:30:51 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/25542448.html#Wed, 6 Jan 2016 07:36:39 GMTMiao, B. et al.

Furthermore, we developed a series of first-in-class EPHA2 inhibitors and show that these new compounds potently induce apoptosis, suppress viability, and abrogate tumorigenic growth of melanoma cells, including those that are resistant to vemurafenib.
Cancer. Discov. 2015; 3:274-87

[See paper]]]>Wed, 6 Jan 2016 07:36:39 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/26312729.html#Thu, 14 Jan 2016 07:41:09 GMTSilva, G.B. et al.

We report fi ve cases of metastatic melanoma with BRAF V600E positivity, treated with Vemurafenib and its cutaneous adverse events.
An. Bras. Dermatol. 2015; 3 Suppl 1:242-6

[See paper]]]>Thu, 14 Jan 2016 07:41:09 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/25926131.html#Wed, 20 Jan 2016 07:45:31 GMTTzoulis, C. et al.

Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report.
BMC. Res. Notes. 2015; 171

[See paper]]]>Wed, 20 Jan 2016 07:45:31 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/25524464.html#Sun, 28 Feb 2016 08:06:17 GMTdel Bufalo, F. et al.

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.
J. Transl. Med. 2014; 356

[See paper]]]>Sun, 28 Feb 2016 08:06:17 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/26900362.html#Sun, 28 Feb 2016 08:06:32 GMTStefan, D. et al.

Vemurafenib and concomitant stereotactic radiation for the treatment of melanoma with spinal metastases: A case report.
Rep. Pract. Oncol. Radiother. 2016; 1:76-80

[See paper]]]>Sun, 28 Feb 2016 08:06:32 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/26985180.html#Thu, 24 Mar 2016 02:14:48 GMTNowara, E. et al.

Patients with skin cancer development during vemurafenib therapy had non-significantly longer overall survival (OS) than patients without skin cancer, p = 0.4.
Postepy. Dermatol. Alergol. 2016; 1:52-6

[See paper]]]>Thu, 24 Mar 2016 02:14:48 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/26989536.html#Thu, 24 Mar 2016 02:16:39 GMTSahadudheen, K. et al.

This also shows clinical safety of Vemurafenib in end stage renal failure and highlights the need for closer look at the subgroup of patients with BRAF V600K mutation and its tumour biology.
Case. Rep. Oncol. Med. 2016; 2672671

[See paper]]]>Thu, 24 Mar 2016 02:16:39 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/25897843.html#Fri, 1 Apr 2016 06:25:23 GMTSondermann, W. et al.

Lymphopenias were observed in 84.6% of patients receiving vemurafenib and dexamethasone.
PLoS. ONE. 2015; 4:e0124590

[See paper]]]>Fri, 1 Apr 2016 06:25:23 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/25956405.html#Wed, 27 Apr 2016 06:43:43 GMTHarding, J.J. et al.

Vemurafenib is highly active in BRAF-mutant melanoma brain metastases but has limited activity in patients with poor performance status.
Oncologist. 2015; 7:789-97

[See paper]]]>Wed, 27 Apr 2016 06:43:43 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/25991583.html#Sat, 7 May 2016 06:49:42 GMTGibney, G.T. et al.

Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
Cancer. Med. 2015; 8:1205-13

[See paper]]]>Sat, 7 May 2016 06:49:42 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/26286452.html#Thu, 14 Jul 2016 06:43:41 GMTProtsenko, S.A. et al.

BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.
Invest. New. Drugs. 2015; 5:1136-43

[See paper]]]>Thu, 14 Jul 2016 06:43:41 GMTBiology and medicineRelated informationhttp://www.wikigenes.org/e/ref/e/26930506.html#Mon, 25 Jul 2016 06:50:45 GMTHurabielle, C. et al.

In 44/52 patients in whom Vemurafenib was discontinued, creatinine levels returned to baseline.
PLoS. ONE. 2016; 3:e0149873

[See paper]]]>Mon, 25 Jul 2016 06:50:45 GMTBiology and medicine